# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 7...
Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and lowers the price target from ...
David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.
Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and raises the price target from ...